AbbVie has successfully completed its acquisition of Aliada Therapeutics, expanding its portfolio in neuroscience research. With the acquisition, Aliada becomes a part of AbbVie, and its lead investigational asset, ALIA-1758, will continue to be developed for the treatment of Alzheimer's disease. ALIA-1758 is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody currently undergoing a Phase 1 clinical trial. The antibody utilizes a novel blood-brain barrier (BBB)-crossing technology, which enhances the delivery of targeted treatments directly into the central nervous system (CNS), potentially offering new hope for Alzheimer's patients.
Dawn Carlson, M.D., M.P.H., Vice President of Neuroscience Development at AbbVie, highlighted the significance of the acquisition, noting "Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age.” She emphasized AbbVie’s commitment to advancing disease-modifying therapies like ALIA-1758 to address the needs of patients. AbbVie aims to leverage Aliada's innovative CNS drug delivery platform to further strengthen its neuroscience discovery and development efforts. With this acquisition, AbbVie continues to push forward in its mission to develop transformative treatments across key therapeutic areas, including immunology, oncology, and neuroscience.
